Blue Lake Biotechnology
2:30 PM - 2:45 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
Blue Lake is a clinical stage company developing novel intranasal vaccines based on parainfluenza virus 5 (PIV5). Our vaccines feature (1) easy administration by nasal spray, (2) mucosal (IgA) immune responses which have the potential to reduce disease transmission, (3) robust and durable immune responses with a single dose, (4) rapid and low cost manufacturing, and (5) a long track record of safe use of PIV5-based vaccines in dogs (which in turn expose their owners).
We have fully enrolled Ph1 trials for our intranasal RSV and COVID vaccines, demonstrating excellent tolerability and cell-mediated immune responses, as well as mucosal and antibody responses, and will be starting Ph2 trials for both programs in 1H23. The RSV vaccine has Fast Track designation from FDA, and will be developed initially for infants/children, a population that current late stage vaccines cannot safely address. Our team includes veterans of FluMist development, the only intranasal vaccine approved in the US.
We have fully enrolled Ph1 trials for our intranasal RSV and COVID vaccines, demonstrating excellent tolerability and cell-mediated immune responses, as well as mucosal and antibody responses, and will be starting Ph2 trials for both programs in 1H23. The RSV vaccine has Fast Track designation from FDA, and will be developed initially for infants/children, a population that current late stage vaccines cannot safely address. Our team includes veterans of FluMist development, the only intranasal vaccine approved in the US.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Georgia
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
BLB201 - vaccine for RSV
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
